|1.||Tong, Wei-Gang: 2 articles (09/2002 - 08/2002)|
|2.||Ding, Xian-Zhong: 2 articles (09/2002 - 08/2002)|
|3.||Adrian, Thomas E: 2 articles (09/2002 - 08/2002)|
|4.||Maier, T J: 1 article (10/2010)|
|5.||Metzner, J: 1 article (10/2010)|
|6.||Steinbrink, S D: 1 article (10/2010)|
|7.||Ulrich, S: 1 article (10/2010)|
|8.||Geisslinger, G: 1 article (10/2010)|
|9.||Fischer, A S: 1 article (10/2010)|
|10.||Angioni, C: 1 article (10/2010)|
03/01/1991 - "Combined use of REV 5901 and indomethacin could become a drug of choice for the treatment of ocular inflammation without inducing corticosteroidal side effects."
01/01/1985 - "Among all lipoxygenase inhibitors studied, REV 5901 was found to be the most potent one to reduce lens protein-induced ocular inflammation in rabbits. "
03/01/1991 - "These results indicate that indomethacin is effective in the early phase of inflammation to reduce PG's production whereas prednisolone and REV 5901 were more effective in the late phase of inflammation. "
01/01/1994 - "It was found that most NSAIAs, including REV 5901, mefenamic acid, indomethacin, CK-17 and CK-102, inhibited lens protein-induced inflammation. "
01/01/1989 - "This method of measuring inflammation was applied to studying the effectiveness of a cyclooxygenase inhibitor, indomethacin, and a lipoxygenase inhibitor, REV 5901, in reducing ocular inflammation induced by lens proteins. "
01/01/1992 - "Whereas treatment with a 5-lipoxygenase inhibitor, PF-5901 (100 mg/kg PO), resulted in a significant reduction of the severity of colitis, concomitant administration of PF-5901 and indomethacin (0.5 mg/kg SC) did not inhibit the exacerbative effects of the indomethacin in this model. "
|3.||Septic Shock (Toxic Shock Syndrome)
06/05/1992 - "In the second study, groups of rats were orally pretreated with PF-5901 (100 mg/kg) or vehicle 3 or 12 h prior to induction of endotoxic shock by i.v. administration of lipopolysaccharide from Salmonella typhosa. "
06/05/1992 - "PF-5901 significantly reduced the hemoconcentration, but not the hypotension associated with endotoxic shock. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
10/01/2010 - "The common 5-LO inhibitors AA-861, Rev-5901 and MK-886 induced cytotoxic and anti-proliferative effects in 5-LO-positive Capan-2 pancreatic cancer cells; BWA4C and CJ-13,610 only caused anti-proliferative effects, while zileuton failed to impair cell viability. "
09/01/2002 - "Apoptosis of pancreatic cancer cells induced by LOX inhibitors (including the nonselective LOX inhibitor nordihydroguaiaretic acid, the 5-LOX inhibitor Rev-5901, and the 12-LOX inhibitor baicalein) was confirmed by growth inhibition, annexin V binding, and terminal deoxynucleotidyl transferase-mediated nick end labeling assay in MiaPaCa-2 and AsPC-1 human pancreatic cancer cells. "
07/01/1989 - "We used computerized image analysis to evaluate quantitatively the ability of topically applied corticosteroids (dexamethasone sodium phosphate, prednisolone acetate), cyclooxygenase inhibitors (flurbiprofen, indomethacin, ketorolac), lipoxygenase inhibitors (REV 5901, esculetin, quercetin), and dual cyclooxygenase/lipoxygenase inhibitors (BW 755C, BW A540C) to reduce corneal neovascularization in the rat induced by silver/potassium nitrate cauterization. "
|2.||Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
|5.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|10.||4,5- Dihydro- 1- (3- (trifluoromethyl)phenyl)- 1H- pyrazol- 3- amine